News

Filter

1 to 9 of 155 results

Positive Ph III results for Portola’s Xarelto antidote andexanet alfa

02-03-2015

USA-based Portola Pharmaceuticals saw its shares jump 7.2% to $40.83 after it announced positive results…

andexanet alfaBayerBiotechnologyCardio-vascularPortola PharmaceuticalsRegulationResearchUSA

Boehringer Ingelheim files BLA with FDA for Pradaxa antidote idarucizumab

02-03-2015

German family-owned pharma major Boehringer Ingelheim has submitted a Biologics License Application (BLA)…

BiotechnologyBoehringer IngelheimCardio-vascularidarucizumabPradaxaRegulationUSA

Amarin in deal with Eddingpharm to commercialize Vascepa in China

Amarin in deal with Eddingpharm to commercialize Vascepa in China

28-02-2015

US biotech firm Amarin has entered into an exclusive agreement for Chinese drugmaker Eddingpharm to develop…

AmarinBiotechnologyCardio-vascularChinaEddingpharmLicensingVascepa

Cell Therapy raises record-breaking crowdfunding for stem cell drug

09-02-2015

UK biotech company Cell Therapy has raised over £691,000 ($1 million) through crowdfunding on Crowdcube…

BiotechnologyCardio-vascularCell therapyCell Therapy LtdFinancialHeartcelUK

Sanofi and Regeneron’s Praluent BLA gains priority review from US FDA

26-01-2015

The US Food and Drug Administration has accepted for priority review the Biologics License Application…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabPraluentRegeneron PharmaceuticalsRegulationSanofiUSA

Aegerion Pharma under SEC investigation

Aegerion Pharma under SEC investigation

14-01-2015

US biotech firm Aegerion Pharmaceuticals has revealed it is the subject of a US Securities and Exchange…

Aegerion PharmaceuticalsBiotechnologyBrazilCardio-vascularJuxtapidLegalMarkets & MarketingRare diseasesUSA

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

12-01-2015

French drug major Sanofi and US biotech company Regeneron have announced that the European Medicines…

alirocumabBiotechnologyCardio-vascularEuropeRegeneronRegulationSanofi

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

09-01-2015

French pharma major Sanofi and Regeneron Pharmaceuticals today announced that two new ODYSSEY trials,…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

1 to 9 of 155 results

COMPANY SPOTLIGHT

Menarini

Back to top